These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35067854)

  • 1. Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab.
    Gkalpakiotis S; Fridman M; Tivadar S
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):605-609. PubMed ID: 35067854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Patient with Adalimumab-Induced Refractory Paradoxical Palmoplantar Pustulosis Was Successfully Treated by Ixekizumab: A Case Report.
    Shao XY; Xiong JX; Chen AJ; Huang K; Wang P
    Clin Cosmet Investig Dermatol; 2023; 16():879-881. PubMed ID: 37038448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
    Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
    Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis.
    Sauder MB; Glassman SJ
    Int J Dermatol; 2013 May; 52(5):624-8. PubMed ID: 23489057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau C; Veyrac G; Dixneuf V; Jolliet P
    Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
    Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
    Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis.
    Wang Y; Cui Y; Zheng Z
    Indian J Dermatol; 2024; 69(2):178-180. PubMed ID: 38841217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
    Menter A; Van Voorhees AS; Hsu S
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
    Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
    J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
    Puig L
    Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab-induced scalp psoriasis with severe alopecia.
    Özkur E; Altunay İK; Leblebici C; Topkarcı Z; Erdem Y
    Dermatol Ther; 2019 Sep; 32(5):e13033. PubMed ID: 31350777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib.
    Zhang ZY; Mi WY; Wang YY; Li W
    J Dermatolog Treat; 2023 Dec; 34(1):2280508. PubMed ID: 37968926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis.
    Rueda-Gotor J; González-Gay MA; Blanco Alonso R; Gonzalez-Vela C; Lopez-Obregon C; González-López MA
    Joint Bone Spine; 2012 Oct; 79(5):510-3. PubMed ID: 22857979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review.
    Lu JD; Lytvyn Y; Mufti A; Zaaroura H; Sachdeva M; Kwan S; Abduelmula A; Kim P; Yeung J
    Int J Dermatol; 2023 Jan; 62(1):12-21. PubMed ID: 35128653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.
    Wendling D; Balblanc JC; Briançon D; Brousse A; Lohse A; Deprez P; Humbert P; Aubin F
    Joint Bone Spine; 2008 May; 75(3):315-8. PubMed ID: 18329935
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.